Patient must have enrolled onto APECSC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APECH based on the presence of an actionable mutation
Patient must have enrolled onto APECSC and must have been given a treatment assignment to molecular analysis for therapy choice (MATCH) to APECB based on the presence of an actionable mutation
Patient must have enrolled onto APECSC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APECG based on the presence of a BRAF V mutation
Patient must have enrolled onto APECSC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APECF based on the presence of an actionable mutation
APECSC: Patient must have enrolled onto APECSC and must have been given a treatment assignment to molecular analysis for therapy choice (MATCH) to APECA based on the presence of an actionable mutation
Patient must have enrolled onto APECSC and must have been given a treatment assignment to MATCH to APECI based on the presence of an actionable mutation\r\n* Positive Rb expression by immunohistochemistry is required for study enrollment
Patient must have enrolled onto APECSC and must have been given a treatment assignment to molecular analysis for therapy choice (MATCH) to APECE based on the presence of an actionable mutation\r\n* Note: patients with BRAF V actionable mutations of interest (aMOIs) will be preferentially assigned to APECG (vemurafenib) if that study is open and they are otherwise eligible for it
Patient must have enrolled onto APECSC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APECC based on the presence of an actionable mutation
